SCHEMBL4634732

SCHEMBL4634732

COC(=O)c1cc(Cl)ccc1OCC(=O)N1CCC(C#N)(Cc2ccc(F)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CCR1 P32246 6/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
SMN1; SMN2 Q16637 6/20 0.42
HTT P42858 3/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 3/20 0.42
TSHR P16473 3/20 0.42
HPGD P15428 2/20 0.42
GAA P10253 2/20 0.42
NPC1 O15118 1/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 2/20 0.41
ALOX12 P18054 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4634285 0.90 CCR1 (0.52) CCR1SMN1; SMN2HTTALDH1A1LMNA
SCHEMBL5674679 0.88 SMN1; SMN2 (0.42) CCR1SMN1; SMN2HTTLMNATSHR
SCHEMBL4635564 0.88 CCR1 (0.43) CCR1KMT2AMEN1SMN1; SMN2HTT
SCHEMBL4634280 0.87 CCR1 (0.45) CCR1KMT2ASMN1; SMN2HTTALDH1A1
SCHEMBL4634937 0.87 CYP2C9 (0.49) CYP2C9CYP2C19CYP1A2CYP3A4CCR1
SCHEMBL5671984 0.87 CCR1 (0.41) CCR1SMN1; SMN2HTTALDH1A1LMNA
SCHEMBL4634679 0.86 CCR1 (0.46) CCR1SMN1; SMN2HTTLMNATSHR
SCHEMBL4635008 0.86 PTGDR2 (0.44) CCR1SMN1; SMN2HTTLMNATSHR
SCHEMBL4634261 0.86 KMT2A (0.44) CYP2C9CYP2C19CYP1A2CYP3A4KMT2A
SCHEMBL4634701 0.86 MAPT (0.47) CCR1SMN1; SMN2HTTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928829-A1 PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS Schering Aktiengesellschaft (DE) 2008-06-11 EP claimed
US-20060167044-A1 Piperidine derivatives and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-07-27 US claimed
WO-2006066948-A1 PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2006-06-29 WO claimed
EP-1928829-A1 PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS Schering Aktiengesellschaft (DE) 2008-06-11 EP disclosed
US-20060167044-A1 Piperidine derivatives and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-07-27 US disclosed
WO-2006066948-A1 PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167044-A1 Piperidine derivatives and their use as anti-inflammatory agents CCR1, CCR2, CCR3 CYP2C9 935/4885CYP2C19 931/4885CYP1A2 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.